Program

20-22 October 2020
RIVE MONTPARNASSE
44 bd de Vaugirard - 75015 Paris
www.ifods.com

President:
Jean-Philippe SPANO - MD, PhD
Paris, France

Comité d’organisation:
Matti Aapro, Jean-Pierre Armand, David Azria, Fabrice Barlesi, Jean-Yves Bley,
Anne Charmasson, Nadine Dehollain, Rosine Guimbaud, Nicolas Girard, Joseph Gilgorev,
Aurélien Gobert, Charles Canova, Nathalie Laquai-Severaud, Thierry Lebret,
Philippe Maingon, Jean-Philippe Metges, Françoise Morineau, Muriel Paul,
Frédérique Penault-Llorca, Edith Perez, Pascal Pujol,
Isabelle Ray-Coquard, Manuel Rodrigues, Sandra Swain,
Thierry Toubiana, Idries Troussier, Jean-Jacques Zambrowski
Dear Friends,

We are pleased and honored to report that the Third Edition of IFODS will be held in Paris from 20-22 October 2020. The Second Edition was a tremendous success, with over 600 participants in attendance. The quality talks and sessions have received such positive feedback across the board that we have decided to go ahead with our plans to create a major national oncology conference, in close collaboration with national oncology societies and leading international experts.

Meanwhile, we must continue to promote this conference to grow attendance year on year and to provide sustained excellence in oncology training. This is why we are moving the event to a more central and accessible location in Paris. This venue is even more conducive to dialogue and communication, everything being on the same floor, whether it be the central forum where partners and participants can interact, the meeting rooms all around, or the auditorium for plenary sessions.

We are looking forward to welcoming you at the Rive Montparnasse business center, which is very close to Montparnasse train station.

As in previous editions, the French Cancer Society (SFC) is working alongside IFODS to organize a special opening session on the Future of Oncology, with contributions from scientists and young oncologists. Institution like EACR is also expected to provide renewed support.

IFODS seeks to promote the efforts of all who fight against cancer, by sharing the best and latest developments in oncology as well as best practice guidelines. In line with this objective, IFODS is delighted to welcome patients and patient groups to its Science Committee meetings and to a number of sessions. The conference will provide these honored guests with opportunities to learn about therapeutic approaches and to confer with healthcare providers.

France is a key player within the global field of oncology and, as such, deserves a world-leading conference on a par with its excellent level of care.

Please join us in Paris from 20-22 October 2020, for the Third Edition of IFODS. As always, pride of place will go to training, dialogue, sharing and excellence in science, in a warm and friendly environment.

Thank you in advance for your support and participation.

We hope to see you there!

With kind regards,

Jean-Philippe SPANO
President of the IFODS Science Committee
SCIENTIFIC SYMPOSIUM ON PROGRAM

Scientific Symposia are sessions during which some of the world best experts will, upon invitation, address different issues related to a specific topic. Each scientific symposium will end with a round table discussion and Q & A with the audience.

TUESDAY 20th OCTOBER

02:00-02:30 PM

▶ PLENARY ROOM

OPENING SESSION : Jean-Philippe SPANO

▶ THE FUTURE OF ONCOLOGY (Basic Science)

LA SEINE (PLENARY) • 02:30-04:30 PM

Under the aegis of SFC, EACR and AACR
President: Manuel Rodrigues
Chairpersons: Jacques-Olivier Bay, Jean-Pierre Armand & Marie Dutreix
02:30–03:00 PM: Future of oncology care / Pr. Axel Kahn (Ligue contre le Cancer)
03:00–03:30 PM: Future of oncology research / Pr. Hugues de Thé (EACR)
03:30–04:00 PM: Artificial intelligence in oncology / Pr. Jean-Philippe Vert (Google Brain)
04:00–04:30 PM: Financial Issues / Pr. Isabelle Durand Zaleski (Henri Mondor Hospital)

04:30-05:00 PM: pause / visite sur les stands / break

▶ AWARDS CEREMONY

LA SEINE (PLENARY) • 05:00-06:00 PM

THESIS on behalf of AERIO, SFC & SFRJO

CLAUDE JACQUILLAT on behalf of SFC
Honorary Presidents: Edith Perez & Sandra Swain

▶ RENCONTRE MÉDECINS - PHARMACIENS : LE PARCOURS PATIENT EN 2020 : UNE APPROCHE MULTIDISCIPLINAIRE AU SEIN D’UN RÉSEAU VILLE – HÔPITAL

MISSISSIPI • 02:30-04:30 PM

Presidents: Georges Garnier
Chairpersons : Anne Charasse, Alain Astier, Bernard DO, Fanny Charbonnier Beauapel, Agnès Bellanger, Patrick Tilleul, Gérard Milano

02:30–03:00 PM: Le parcours de la biopsie liquide. Gérard Milano
04:30-05:00 PM: pause / visite sur les stands / break

▶ POSTERS SESSION

▶ SESSION INFIRMIÈRES RECHERCHES EN SOINS, DE L’IDÉE À LA CLINIQUE INFIRMIÈRE

ST LAURENT • 02:30-05:00 PM

Under the aegis of AFIC
Présidente: Pascale Dielenseger
Modérateurs: Pascale Dielenseger, Pierre Perroche

- Recherche infirmière : quelle ossature de protocole ? Pascale Dielenseger, cadre de santé, IGR, VILLEJUIF


- Suivi renforcé des patients sous thérapies anticancéreuses orales : mise en œuvre d’un programme de recherche paramédicale financé dans le cadre d’un PHRIP” Pierre Perroche, cadre de santé, CGFL, DIJON

* to be confirmed
WEDNESDAY 21st OCTOBER

CONSENSUS AND GUIDELINES FOR BREAST CANCER (1)

INNOVATION: ACCELERATE OR SLOW DOWN

LA SEINE (PLENARY) • 09:00-12:30 AM

Under the aegis of St Paul
Presidents: Marc Spielmann, Joseph Gligorov

PART I: ACCELERATE AND SLOW DOWN

9:00–10:00 AM: Endocrine receptor positive breast cancers: are we moving to the end of the endocrine treatment alone?

9:00–09:20 AM: CDK4/6 inhibitors in ER positive MBC: Who do not benefit? Véronique Dieras

9:20–09:40 AM: PIK3CA inhibitors in PIK3CAmut ER positive MBC: Who not to test? Suzette Delaloge

9:40–10:00 AM: Optimizing endocrine treatment in EBC: What have we learn from TailorX and MINDACT trials? Johanna Wassermann

10:00 – 10:30 AM: pause / visite sur les stands / break

10:30–11:30 AM: HER2 positive breast cancers: is it time to redefine the disease and the treatment strategies?

With the support of ROCHE

10:30–10:50 AM: Is the neoadjuvant strategy in HER2 positive breast cancers the optimal one? Jean-Yves Pierga

10:50–11:10 AM: Clinical interest of redefining HER2 positive disease? Frédérique Penault-Llorca

11:10–11:30 AM: New strategies in HER2 positive MBC? Sandra Swain

13:30 PM–14:00 PM

LUNCH COCKTAIL

LA LEÇON DES IFODS

LA SEINE (PLENARY) • 02:00-02:30 PM

Chairpersons: Edith Perez & Frédérique Penault-Llorca
Speaker: Jérôme Galon
Predictive factors in Immunotherapy: a signature or a Score?

CONSENSUS AND GUIDELINES FOR BREAST CANCER (2)

INNOVATION: ACCELERATE OR SLOW DOWN

LA SEINE (PLENARY) • 02:30-03:30 PM

Under the aegis of St Paul

02:30–02:50 PM: Immune checkpoint therapies in triple negative breast cancers: a new standard? Edith Perez

02:50–03:10 PM: Systemic treatment for early breast cancers: any impacting news? (TBD)

03:10–03:30 PM: Towards more neoadjuvant chemotherapy? How should the surgeon fit? Catherine Uzan

THE NEWS OF 2020 IN CARCINOLOGICAL GYNECOLOGY (SGO, ASCO, ESMO)

LA SEINE (PLENARY) • 03:30-04:30 PM

Under the aegis of SFCO & GINECO GROUP

Presidents: Jean-Marc Classe & Isabelle Ray-Coquard
Chairpersons: Jérôme Alexandre and Jean-Marc Classe

- Endometrial cancer: Renaud SABATIER
- Ovarian cancer: (TBD)
- Cervical cancer: Jérôme MARTIN-BABAU

POSTERS SESSION
WEDNESDAY 21st OCTOBER

GÉNOMIC SEQUENCING FOR ALL PATIENTS?
LA SEINE (PLENARY) • 04:30-05:30 PM
Under the aegis of St Paul & SFMPP
With the support of GSK

Presidents: Pascal Pujol, Joseph Gligorov & Frédérique Penault-Llorca
04:30–04:50 PM: cancer genomics at Germline level: what’s new in the era of multigene panel? Thibault de La Motte Rouge (TBC)
04:50–05:10 PM: Are we getting closed to extend circulating tumoral DNA use in clinical practice: Interest for récurrence detection in ovarian cancer? Véronique Haddad
05:10–5:30 PM: Clinical guidelines for BRCA1/2 genetic testing in the era of PARP inhibitors: an overview and the recommendations of the SFMPP. Frédérique Penault-Llorca

5:30-5:45 PM: pause / visite sur les stands / break

► CONSENSUS AND GUIDELINES FOR GI TUMORS
MISSISSIPPI • 09:00-12:30 AM
Under the aegis of Prodige Group, UNICANCER GI, GERCOR & FFCD

Chairperson: Christophe Louvet
9:40–10:00 AM: IDEA lessons beyond treatment duration. Thierry André
10:00–10:20 AM: Follow-up after colon cancer surgery. Côme Lepage

Discussion (10 minutes)

10:30 – 11:00 AM: pause / visite sur les stands / break

11:00–11:30 AM: Beyond Folfirinox and Gem Abraxane, what else in advanced pancreatic cancer treatment? (TBD)
11:30–11:50 AM: Oncogenetic and GI cancers. Rosine Guimbaud
11:50–12:10 AM: Metastatic colorectal cancer: 3rd line and after. Emmanuelle Samalin

12:20–12:30 AM
Conclusion. Christophe Louvet

► 12:30 AM-02:00 PM
MISSISSIPPI • LUNCH/DEBATE
PAN TUMORS
With the support of Pierre Fabre

► CONSENSUS AND GUIDELINES FOR DERMATOLOGY
MISSISSIPPI • 02:30-04:00 PM

Presidents: Celeste Lebbe
Chairpersons: Barouyr Baroudjian, Donia Lassoued & Stéphane Barete
2:30–2:45 PM: Adjuvant and neoadjuvant treatment of melanoma. Barouyr Baroudjian
2:45–3:00 PM: New therapeutic combinations: news from the AACR. Cristina Libenciuc
3:00–3:15 PM: How to monitor our long-term responders? Lise Boussemart
3:15–3:30 PM: What are the serious toxicities of immunotherapy? Caroline Dutriaux
3:30–3:45 PM: Management of brain and meningeal metastases. Jérêmy Lupu

Discussion (15 minutes)

DUETS SESSION
BISPECIFIC ANTIBODIES AND CAR T CELLS: ALONE OR IN COMBINATION?
MISSISSIPPI • 04:00-05:00 PM

Presidents: Edith Perez & Fanny Charbonnier
Speakers: Paul Gougis & Nicolas Poirier
CART-cells in the field of solid tumors. Paul Gougis
Bispecific Anti-PD1 to Tackle Immune Resistance Mecanism. Nicolas Poirier

* Late Breaking Abstract
CONSENSUS AND GUIDELINES FOR UROLOGY
TRI-MODAL TREATMENTS: FOR OR AGAINST?

ST LAURENT • 09:00-12:30 AM

**Under the aegis of AFU**

Presidents: Thierry Lebret, David Azria, Ronan Flippot & Arnaud Méjean

3 CLINICAL CASES: FOR / AGAINST

1. Kidney: 62-year-old man bilateral kidney tumor with vascular thrombus on the right and a single synchronous meta on the lung
   Place of surgery (total + partial + metastasectomy) and discussion of adjuvant tKi
   Idir Ouzaid
   TKi treatment without surgery. Yann Alexandre Vano
   - Discussion and conclusion: Ronan Flippot

2. Urothelium: 62-year-old T2G3 bladder man, resection deemed complete and Tep Scan negative.
   Why offer a complete resection with radio-chemotherapy ?David Azria
   Why not offer this solution ?Alexandra Masson Lecomte
   - Discussion and conclusion: Thierry Lebret

3. Prostate: 62 year old man Gleason 8 (4 + 4), clinical T2 doubt on T3 MRI and PSA at 16ng / ml.
   Place of primary surgery associated with radio-hormone therapy. François Rozet
   Why stay at Bolla without first surgery. (TBD)
   - Discussion and conclusion: Arnaud Méjean

12:30-2:00 PM ST LAURENT •

CONSENSUS AND GUIDELINES FOR RADIOTHERAPY

ST LAURENT • 02:30-05:00 PM

**Under the aegis of SFRO**

President: Philippe Giraud

Chairpersons: David Azria, Florence Huguet, Philippe Maingon, Françoise Mornex

Proton Therapy - Validated Indications and Prospects in France. Jérôme Doyen

New dose constraints in radiotherapy of brain tumors, based on the cognitive impairment and morphological changes after radiation therapy. Julian Jacob

State of the art of radiobiology and its projects in France in 2020. David Azria

Recommendations for radiotherapy of a patient with a pacemaker / defibrillator. Marc Laurans

Computer system safety in Radiation Oncology. Charlotte Drapeau

5:00-5:30 PM: pause / visite sur les stands / break

POSTERS SESSION

11:15-12:30 AM: SYMPOSIUM
  **With the support of IPSEN**

10:30-11:00 AM: pause / visite sur les stands / break
THURSDAY 22nd OCTOBER

▷ CONSENSUS AND GUIDELINES FOR LUNG CANCER

• LA SEINE (PLENARY) • 09:00-12:30 AM

* Under the auspices of our respective groups: IFCT, Oncology Group/SPLF

Présidents: Marie Wislez, Fabrice Barlesi
Chairperson(s): Françoise Mornex, Frances Shepherd, Pierre-Jean Souquet

09:00-09:30 AM: what are and what would be the biomarkers to look for to predict the efficacy of immunotherapy? Éric Tartour
09:30-10:00 AM: How and why genotype naive advanced NSCLC pts? Federico Capuzzo
10:00-10:30 AM: Which first-line treatment for NSCLC patients without addiction? Maurice Pérol

10:30-11:00 AM: pause / visite sur les stands / break

11:00-11:30 AM: How to manage EGFR and ALK resistances in 2020? Enriqueta Felip
11:30-12:00 AM: Initiatives to improve efficacy, accessibility and affordability of lung cancer care in the future? The IASLC pathway. Giorgio Scagliotti
Discussion

▷ POSTERS SESSION

• 12:30PM-13.30 PM

* LA SEINE (PLENARY) • IMMUNOTHERAPY HIGHLIGHTS FITI* SESSION (International Meetings Update)

* With the support of MSD

• 13:30 PM-14:00 PM

LUNCH COCKTAIL

▷ ATELIER SPORT & CANCER

• LA SEINE (PLENARY) • 02:00-04:30 PM

* Under the aegis of CAMI

Présidents: Thierry Bouillet & Jean-Marc Descotes

« Présentation de l’Enquête co-menée avec le Laboratoire PFIZER sur les leviers et freins à la pratique de l’activité physique adaptée chez des patients atteints de cancer métastatique »

13h30 : Accueil
14h00 : Introduction. Thierry Bouillet (Co-fondateur et Président de la CAMI Sport & Cancer)
14h15 : Présentation de l’enquête et des résultats. (TBD)
15h15 : Table Ronde – Quels enseignements tirés de cette enquête? (TBD)
16h : Intervention de deux grands témoins. (TBD)
16h20 : Conclusion Jean-Marc Descotes (Co-fondateur et Directeur Général de la CAMI Sport & Cancer)

▷ POSTERS AWARD

▷ LA PAROLE EST AUX PATIENTS

ST LAURENT • 09:00-10:30 AM

Sous l’égide des associations de patients, Europa Donna, Life is Rose, Rose Magazine
Université des patients Sorbonne Université, Nathalie Savariaud, Jean-Jacques Zambrowski, Maryline Baranes, Natacha Espié, Gary Rodin, Françoise Debiais, Édith Perez, Joseph Gligorov, Laure Accolas, Céline Dupré et Céline Lis-Raoux

09:00-10:30 : Les problèmes sociaux et de logement rencontrés au moment et après la maladie

▷ « INNOVATION RELATIONNELLE »

Bénéfices-Risques dans la relation Médecin-Patient et dans la mise en place des traitements : le cas de la simulation d’annonce en Oncologie

ST LAURENT • 11:00-12:00 AM

▷ LA SOFOM AUX IFODS

ST LAURENT • 12:00-12:30 AM

▷ 12:30PM-13.00 PM • FLASH MEET THE PROFESSOR

* With the support of LEO PHARMA
THURSDAY 22nd OCTOBER

➤ MANAGEMENT OF CARDIOVASCULAR COMPLICATIONS IN CANCER PATIENTS

ST LAURENT • 02:00-03:30 PM
Chairperson(s): Joe-Elie Salem (Paris), Francis Cajfinger (Paris)
1. Myocarditis Induced by Immune-Checkpoint Inhibitors: Clinical features, management, and outcomes. Stéphane Ederhy (Paris)
3. Clinical features and Management of Atrial Fibrillation in Cancer Patients. Joaquim Alexandre (Caen)

➤ BIOTECH IN ONCOLOGY

ST LAURENT • 03:30-05:00 PM
Under the aegis of Gustave Roussy
Transfert, Cancer Campus and Anges Santé
Startup Showcase Session (open to academic projects and start-ups): presentation pitch of your project (7 min) in front of the IFODS audience in the presence of experts, investors and potential partners
Networking session with investors, pharmas, oncologists, researchers

➤ HOW TO MANAGE BREAST CANCER ACCORDING TO THE MEANS: « THE MINIMAL REQUIREMENTS AND STANDARDS » AROME CONCEPT

MISSISSIPPI • 09:00-11:00 AM
Sous l’égide de AROME
Chairperson(s): Joseph Gligorov, Yazid Belkacemi
1. Introduction. Joseph Gligorov (AROME President)
2. Minimal requirements for diagnosis: Is MRI a minimal requirement for breast cancer imaging. Thu Ha Dao
The Pathology report: from minimal to standard. Nina Radosevic
3. Loco-regional therapy: Is SLNB the minimal for all BC. Marie Pierre Chauvet
Is hypofractionation breast RT the standart For all patients with BC in emergent countries. Yazid Belkacemi
4. Access for innovation in systemic therapy:
A report from the AROME Budva Consensus. Joseph Gligorov
Discussion and Closing remarks

➤ CONSENSUS AND GUIDELINES FOR SARCOMA

MISSISSIPPI • 11:00-12:30 AM
Under the aegis of GSF-GETO & NET-SARC
Presidents: Jean-Yves Blay & Axel Le Cesne
Chairperson: Aurore Vozy, Sixtine De Percin
What’s new in 2020?
• Surgery
• Radiotherapy
• Chemotherapy
• Targeted Immunotherapy
• Central role of CPR, « A multidisciplinary approach »

➤ 12:30PM-13:30 PM
MISSISSIPPI • SYMPOSIUM
" SMALL CELL LUNG CANCER : ADVANCES AND CHALLENGES" With the Support of AstraZeneca
Chairperson(s): Marie Wislez, Fabrice Barlesi, Virginie Westeel
Towards a new characterization of small cell lung cancers? Immunobiological aspects and new molecular classification. Audrey Lupo
Is there a new standard in small cell lung cancer therapy? Frances Shepherd
Prospects and challenges: towards personalized treatment? Gerard Zalcman

➤ CONSENSUS AND GUIDELINES FOR LUNG CANCER (2)

MISSISSIPPI • 02:00-03:30 PM
Under the auspices of our respective groups: IFCT, Oncology Group/SPLF
Présidents: Marie Wislez, Fabrice Barlesi
Chairperson(s): Virginie Westeel, Céline Mascaux
02:00-02:30 PM: Smoking cessation: benefits and risks of vap. Anne-Marie Ruppert
02:30-03:00 PM: How to best organize the multimodality management of lung cancer patients? Laurent Greillier
03:00-03:30 PM: Is there a new hope for ECOG PS2+/comorbidities patients? Sanjay Popat

* FITI : From IFODS TO IFODS
THURSDAY 22nd OCTOBER

INTERACTIVE WEBCONFERENCE:
MULTIDISCIPLINARY BOARD/BONE METS OF LUNG CANCER

MISSISSIPPI • 03:30-04:30 PM
Sous l’égide du groupe GEMO
Presidents: Marie-Hélène Vieillard & Frédéric Clarençon
Chairperson(s): Laetitia Morardet, Matti Aapro

04:30-05:00 PM: pause / visite sur les stands / break
Abstracts have to be submitted electronically and in English. Abstracts received after the deadline (September 10th, 2020) will not be considered. Supply as much information as possible: the precise subject of study, methods used where appropriate, summary of results obtained, conclusion. As it is assumed that original work will be presented, no bibliographic references are necessary. Selected abstracts will be published in the abstract book exactly as you submitted it. Therefore, proofreading is essential; no modification will be possible after submission. Your abstract should not contain accents or any other invalid character, which would not be part of the English alphabet. Your abstract’s text should not exceed 3,000 characters (excluding spaces). The main author (presenter) confirms that all authors are aware of and agree to the content of the abstract and support of the data presented. By submitting his abstract, the author allows the IFODS to publish and distribute or sell his abstract as part of the Abstract Book, which may be distributed on paper. All selected abstracts will be published in the abstract book. Papers accepted for IPOSTER presentation will be displayed during poster sessions. Acceptance or rejection of the paper by the Scientific Committee will be notified by email to the main author (presenter) by September 14th, 2020. Only persons whose registration is complete will be able to present their abstracts. IPOSTERS will be awarded or encouraged: a special jury will select the three best posters and their authors will receive IFODS Poster Award and a cheque of 500€ each.

**REGISTRATION FEES (in Euros)**

<table>
<thead>
<tr>
<th></th>
<th>1 Day Regular Registration</th>
<th>Regular Registration</th>
</tr>
</thead>
</table>
| From Nov. 15th to June. 15th 2020 | ☐ 200 € | ☐ Tuesday October 20th 2020  
|                         | ☐ 200 € | ☐ Wednesday October 21st 2020  
|                         | ☐ 200 € | ☐ Thursday October 22nd 2020  |
| From June 16th 2020 and on site | ☐ 250 € | ☐ Tuesday October 20th 2020  
|                         | ☐ 250 € | ☐ Wednesday October 21st 2020  
|                         | ☐ 250 € | ☐ Thursday October 22nd 2020  |
| Student registration fees (Including breaks and 2 lunch) | ☐ 100 € | (The participation of student is conditioned by the full coverage of their hospitality costs) |

**WAY OF REGISTRATION**

Online Registration: secure online registration and payment by credit card via the website [www.ifods.com](http://www.ifods.com). Registration will be validated only with payment by credit card (Visa, Mastercard). Registration Form sent by Fax or Mail: you can download the registration form on the website and send it duly completed to the Organisation Committee. Registration will be validated only with payment attached or credit card information completed. Cancellation Policy: Before July 10th, 2020: 50% cancellation fees. From July 11th, 2020: no refund.

Contact: Valérie CAILLON : Tel.: +33 1 41 04 04 04 - Fax: +33 1 41 04 04 11 Email: valerie.caillon@im-events.com

Contact: Mathilde MANGIN : Tel.: +33 1 41 04 04 04 - Fax: +33 1 41 04 04 11 Email: mathilde.mangin@im-events.com
 Whether you are the organiser or the participant, the Global Meetings Program allows you to benefit from the expertise of SkyTeam’s network covering over 1,000 destinations worldwide. Via the online portal, not only can participants obtain discounted travel, but flights and connections are made more convenient. Organisers can also take advantage of an online solution especially designed to meet their needs, including a productivity reward program. Additionally, we provide you with a communications kit and one point of contact to help manage your event. Visit our website www.skyteam.com/globalmeetings.

AIR FARE DISCOUNT - Event ID : 36 189 AF

SkyTeam Global Meetings Agreement - This Agreement is entered into by and among member airlines of the SkyTeam Alliance and EQUATOUR. The airlines of SKYTEAM, Official Alliance Network for the IFODS 2020, offer attractive airfares for participants. SKYTEAM comprises 19 leading international airlines serving 1000 destinations in 187 countries with over 15 000 flights daily.

GLOBAL MEETINGS PROGRAM - TICKETS PURCHASING

The Discount Agreement will be for travel between June 2nd through June 18th, 2020. To benefit from these special offers, link up with http://globalmeetings.skyteam.com and quote the Identifier Code 36 189 AF Tickets purchased on the following Carriers are eligible for the SkyTeam Global Meetings programme:


To book your travel now, visit www.skyteam.com/GlobalMeetings and enter your Event ID, 36 189 AF

Through this site you can also access the schedules of all SkyTeam partners to plan your flights on the airline of your choice.